A Randomized, Double-Blind, Placebo-Controlled Trial Protocol Using the Fuzhengxiaoliu Patch for the Management of Primary Liver Cancer Pain

被引:0
|
作者
Li, Siman [1 ]
Wang, Binding [1 ]
Deng, Jiayao [2 ]
Li, Haiyan [2 ]
Wu, Yong [3 ]
Fang, Yu [2 ]
Yan, Bohua [2 ]
Chen, Yu [2 ]
机构
[1] Chengdu Univ TCM, Sch Clin Med, Chengdu, Sichuan, Peoples R China
[2] Hosp Chengdu Univ Tradit Chinese Med, Chengdu, Sichuan, Peoples R China
[3] Chengdu Zhongxiang Pharmaceut Technol Co Ltd, Chengdu, Sichuan, Peoples R China
来源
JOURNAL OF PAIN RESEARCH | 2025年 / 18卷
关键词
primary liver cancer; traditional Chinese medicine; Chinese herb; cancer pain management; randomized controlled trial; MECHANISMS;
D O I
10.2147/JPR.S500305
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Chronic pain strongly affects the quality of life of patients with liver cancer pain. Safe and effective management of cancer- related pain is a worldwide challenge. Traditional Chinese medicine (TCM) has rich clinical experience in the treatment of cancer pain. The Fuzhengxiaoliu patch (FZXLP) is a compound TCM with the effects of detoxification and pain relief and has shown great efficacy in the treatment of patients with liver cancer, but high-quality clinical research that provides research-based evidence is lacking. We designed a randomized, double-blind, placebo-controlled trial to explore and evaluate the efficacy of FZXLP for the treatment of liver cancer pain. Methods: This is a prospective, randomized, double-blind, placebo-controlled trial. The trial will enrol 72 participants with primary liver cancer with cancer pain (damp-heat stagnation and toxin and blood stasis syndrome). The primary objective is to measure the reduction in pain using FZXLP in combination with tegafur, gimeracil and oteracil potassium capsule (S-1) compared to the placebo group with S-1. Pain will be measured by the number of opioids used, Chinese versions of the numerical rating scale (NRS), pain relief rate and number of breakthrough cases of cancer pain (BTcP). The secondary objectives include response evaluation criteria in solid tumors (RECIST), tumor markers, TCM syndrome scores, weight, functional assessment of cancer therapy-hepatobiliary (FACT-Hep) questionnaire scores, and self-rating anxiety scale scores. Adverse events (AEs) will be recorded throughout the study. Discussion: This study integrated TCM with clinical research to assess the efficacy and safety of the addition of FZXLP in the treatment of primary liver cancer pain. Trial registration: Chinese clinical trial registry, ChiCTR2300076951, Registered on October 25, 2023. https://www.chictr.org.cn/ showproj.html?proj=209608.
引用
收藏
页码:33 / 42
页数:10
相关论文
共 50 条
  • [31] Prednisone for patients with recurrent implantation failure: study protocol for a double-blind, multicenter, randomized, placebo-controlled trial
    Lu, Yao
    Yan, Junhao
    Liu, Jiayin
    Tan, Jichun
    Hong, Yan
    Wei, Daimin
    Chen, Zi-jiang
    Sun, Yun
    TRIALS, 2020, 21 (01)
  • [32] Effect of pramipexole on RLS symptoms and sleep: A randomized, double-blind, placebo-controlled trial
    Ferini-Strambi, Luigi
    Aarskog, Dagfinn
    Partinen, Markku
    Chaudhuri, K. Ray
    Sohr, Mandy
    Verri, Daniela
    Albrecht, Stefan
    SLEEP MEDICINE, 2008, 9 (08) : 874 - 881
  • [33] A Randomized, Double-Blind, Placebo-Controlled Trial of Citicoline in Patients with Alcohol Use Disorder
    Brown, E. Sherwood
    Van Enkevort, Erin
    Kulikova, Alexandra
    Escalante, Chastity
    Nakamura, Alyson
    Ivleva, Elena I.
    Holmes, Traci
    ALCOHOL-CLINICAL AND EXPERIMENTAL RESEARCH, 2019, 43 (02): : 317 - 323
  • [34] Results of a randomized, double-blind, placebo-controlled trial of lorcaserin in cocaine use disorder
    McCann, David J.
    Chen, Hegang H.
    Devine, Eric G.
    Gyaw, Shwe
    Ramey, Tatiana
    DRUG AND ALCOHOL DEPENDENCE, 2024, 255
  • [35] Individualized Homeopathic Medicines in Chronic Rhinosinusitis: Randomized, Double-Blind, Placebo-Controlled Trial
    Misra, Pankhuri
    Nayak, Chintamani
    Chattopadhyay, Abhijit
    Palit, Tarun Kumar
    Gupta, Bharti
    Sadhukhan, Satarupa
    Bhar, Koushik
    Rai, Shruti
    Parewa, Maneet
    Ali, Sk Swaif
    Basu, Anamika
    Nath, Arunava
    Koley, Munmun
    Saha, Subhranil
    HOMEOPATHY, 2021, 110 (01) : 13 - 26
  • [36] Efficacy of naproxen in patients with sciatica: multicenter, randomized, double-blind, placebo-controlled trial
    Grovle, Lars
    Hasvik, Eivind
    Holst, Rene
    Saetre, Anders
    Brox, Jens Ivar
    Mathiassen, Stale
    Myhre, Kjersti
    Holmgard, Thor Einar
    Haugen, Anne Julsrud
    PAIN, 2024, 165 (11) : 2606 - 2614
  • [37] Effect of Vitamin D on Endothelial Function: A Randomized, Double-Blind, Placebo-Controlled Trial
    Borgi, Lea
    McMullan, Ciaran
    Wohlhueter, Ann
    Curhan, Gary C.
    Fisher, Naomi D.
    Forman, John P.
    AMERICAN JOURNAL OF HYPERTENSION, 2017, 30 (02) : 124 - 129
  • [38] Randomized, double-blind, placebo-controlled trial of autologous blood therapy for atopic dermatitis
    Pittler, MH
    Armstrong, NC
    Cox, A
    Collier, PM
    Hart, A
    Ernst, E
    BRITISH JOURNAL OF DERMATOLOGY, 2003, 148 (02) : 307 - 313
  • [39] Gamified Web-Delivered Attentional Bias Modification Training for Adults With Chronic Pain: Protocol for a Randomized, Double-blind, Placebo-Controlled Trial
    Vermeir, Julie F.
    White, Melanie J.
    Johnson, Daniel
    Crombez, Geert
    Van Ryckeghem, Dimitri M. L.
    JMIR RESEARCH PROTOCOLS, 2022, 11 (01):
  • [40] Kalium phosphoricum comp. in patients with neurasthenia: a randomized, double-blind, placebo-controlled clinical trial
    Hellhammer, Juliane
    Spitznagel-Schminke, Luitgard
    Hufnagel, Rebecca
    CURRENT MEDICAL RESEARCH AND OPINION, 2024, 40 (02) : 239 - 251